In the latest trading session, 1.03 million Sangamo Therapeutics Inc (NASDAQ:SGMO) shares changed hands as the company’s beta touched 1.15. With the company’s most recent per share price at $2.24 changed hands at -$0.02 or -0.88% at last look, the market valuation stands at $459.24M. SGMO’s current price is a discount, trading about -41.96% off its 52-week high of $3.18. The share price had its 52-week low at $0.30, which suggests the last value was 86.61% up since then. When we look at Sangamo Therapeutics Inc’s average trading volume, we note the 10-day average is 5.67 million shares, with the 3-month average coming to 7.30 million.
Analysts gave the Sangamo Therapeutics Inc (SGMO) stock a consensus recommendation rating of Hold, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended SGMO as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Sangamo Therapeutics Inc’s EPS for the current quarter is expected to be 0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Sangamo Therapeutics Inc (NASDAQ:SGMO) trade information
Instantly SGMO was in red as seen in intraday trades today. With action 19.15%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 312.30%, with the 5-day performance at 19.15% in the green. However, in the 30-day time frame, Sangamo Therapeutics Inc (NASDAQ:SGMO) is 31.76% up. Looking at the short shares, we see there were 13.39 million shares sold at short interest cover period of 0.99 days.
The consensus price target for the stock as assigned by Wall Street analysts is 12, meaning bulls need an upside of 81.33% from its recent market value. According to analyst projections, SGMO’s forecast low is 5 with 19 as the target high. To hit the forecast high, the stock’s price needs a -748.21% plunge from its current level, while the stock would need to soar -123.21% for it to hit the projected low.
Sangamo Therapeutics Inc (SGMO) estimates and forecasts
Data shows that the Sangamo Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 284.35% over the past 6 months, a 11.86% in annual growth rate that is considerably lower than the industry average of 17.70%. Year-over-year growth is forecast to reach -65.51% down from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 10.32M. 3 analysts are of the opinion that Sangamo Therapeutics Inc’s revenue for the current quarter will be 31.5M. The company’s revenue for the corresponding quarters a year ago was 2.04M and 481k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 405.22%. The estimates for the next quarter sales put growth at 6,448.86%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -15.96%. The 2024 estimates are for Sangamo Therapeutics Inc earnings to increase by 66.60%.
SGMO Dividends
Sangamo Therapeutics Inc is expected to release its next quarterly earnings report in January.
Sangamo Therapeutics Inc (NASDAQ:SGMO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.36% of Sangamo Therapeutics Inc shares while 27.07% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 27.73%. There are 27.07% institutions holding the Sangamo Therapeutics Inc stock share, with WASATCH ADVISORS LP the top institutional holder. As of 2024-06-30, the company held 11.1403% of the shares, roughly 20.09 million SGMO shares worth $7.2 million.
ARMISTICE CAPITAL, LLC holds the second largest percentage of outstanding shares, with 7.7963% or 14.06 million shares worth $5.04 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Wasatch Ultra Growth Fund and Wasatch Microcap Fund. With 10.97 shares estimated at $24.2 million under it, the former controlled 5.26% of total outstanding shares. On the other hand, Wasatch Microcap Fund held about 2.71% of the shares, roughly 5.65 shares worth around $12.46 million.
